Top Message

Since our founding in 1942, we have grown for over 80 years as a trading company and as a manufacturer of active pharmaceutical ingredients (APIs) and drug products. We will continue to contribute to better health of patients and a healthier society by manufacturing pharmaceutical products.

Our management philosophy declares as follows: “We will create a favorable workplace environment where every employee can find ‘joy in working at a cheerful company.’” We will ensure that our employees can find their work joyful and that the growth of the Company links together with the growth of every employee, aiming to be a company that can continue to be chosen by customers.

In recent years, the business environment surrounding us has become increasingly harsher due to changes in governmental pharmaceutical policies and regulations, industry trends, and the financial and capital markets. To overcome these changes and increase our corporate value, we formulated "Daito Transformation Plan 2027 (DTP2027)", a new Medium-term Management Plan, in July 2024.

The concept of DTP2027 is establishing “Shin” Daito, and its name includes the word “transformation,” reflecting our conviction that we must change.

DTP2027 envisions that, as our business strategy, we will streamline the existing businesses, strengthen our China business, and enter into new businesses with the aim of increasing our corporate value over the long term. In addition, to support our measures to implement these strategies, we will proactively address a PBR of below 1.0, enhance capital allocation, and invest in human capital.

Furthermore, we will also streamline our operational processes and create new value by promoting digital transformation (DX). By doing so, we will build our corporate capabilities to respond more swiftly and more flexibly to changes in the market.

Moreover, we will enhance our environmental, social and governance (ESG) initiatives to realize a sustainable society in order to fulfill our social responsibility and achieve sustainable corporate growth.

Finally, staying profoundly aware that the pharmaceutical products of Daito Pharmaceutical Co., Ltd. are linked to people’s lives and health, all of us at Daito promise to observe laws and regulations as members of a life-related company and to supply high-quality products by upholding a high standard of ethics and responsibility.

President and CEO Hiroshi Matsumori